| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dca52c731f5284d36e33936016d3fe49 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-546
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-546 |
| filingDate |
2018-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abe457a213b40fbee553f2491b8c79a4 |
| publicationDate |
2019-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018203238-A1 |
| titleOfInvention |
Use of ceftriaxone in the manufacture of a medicament for the treatment of dementia with lewy bodies |
| abstract |
Ceftriaxone is to be administrated to a subject suffered from dementia with Lewy bodies (DLB) to treat the DLB syndromes such as cognitive decline and neurological deficit in the subject thereof. Ceftriaxone can be 5 parenterally or orally administrated to the subject in a dosage of 1.5-35 mg/kg/day. 04* -o |
| priorityDate |
2017-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |